secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001854270-24-000027
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio reports FY2023 net loss of $71.1M; cash runway into Q1 2025; IND cleared for SENTI-202 AML therapy
--------------------------------------------------------------------------------

- Net loss for FY2023 was $71.1M ($1.60/share) vs $58.2M in FY2022.
- Cash, cash equivalents and short-term investments of $35.9M at 12/31/2023; plus $18.9M GeneFab receivable to fund into Q1 2025.
- R&D expenses $32.2M (FY2023), G&A $37.2M; net loss includes $12.3M gain from discontinued operations and $25.7M impairment.
- FDA cleared IND for SENTI-202 (logic-gated CAR-NK for AML); first patient dosing expected Q2 2024, initial efficacy data by year-end 2024.
- Collaboration with Celest for SENTI-301A (HCC) in China; first patient dosing expected Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000027/0001854270-24-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000027/snti-20240321.htm
  HTML page:      https://secwatch.observer/filing/0001854270-24-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer